Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
August 7, 2025
Company name: KAKEN PHARMACEUTICAL CO., LTD.
Stock exchange listing: Tokyo Stock Exchange Securities code number: 4521
URL: https://www.kaken.co.jp/english/
Representative: Hiroyuki Horiuchi, President and Representative Director
Contact: Yasuhiko Kondo, General Manager of Accounting & Finance Department Telephone: +81-3-5977-5007
Scheduled date of dividend payment commencement: -
Supplementary materials for financial results: Yes
Financial results briefing: None
(Amounts are rounded down to the nearest million yen)
-
Consolidated Financial Results for the Three-Month Period of Fiscal 2025 (April 1, 2025 to June 30, 2025)
-
Consolidated Operating Results (cumulative) (Percentage indicates year-on-year change)
Net sales
Operating profit
Ordinary profit
Profit attributable to
owners of the parent
(Million yen)
(%)
(Million yen)
(%)
(Million yen)
(%)
(Million yen)
(%)
Three-Month period of Fiscal 2025
18,867
3.4
14
(99.5)
417
(86.1)
271
(84.5)
Three-Month period of Fiscal
2024
18,254
0.6
2,750
(16.5)
3,011
(13.7)
1,754
(30.1)
Note:
Comprehensive income:
Three-Month period of Fiscal 2025: ¥ 40 million [(97.5)%]
Three-Month period of Fiscal 2024: ¥ 1,607 million [(57.8)%]
Basic earnings
per share
Diluted earnings
per share
(Yen)
(Yen)
Three-Month period of Fiscal 2025
7.13
-
Three-Month period of Fiscal
2024
46.32
-
- Consolidated Financial Position
Total assets
Net assets
Equity-to-asset ratio
(Million yen)
(Million yen)
(%)
As of June 30, 2025
176,341
147,447
83.6
As of March 31, 2025
190,422
152,634
80.2
Reference:
Equity:
As of June 30, 2025: ¥ 147,447million As of March 31, 2025: ¥ 152,634 million
-
Consolidated Operating Results (cumulative) (Percentage indicates year-on-year change)
-
Cash Dividends
Annual dividends per share
1st quarter
2nd quarter
3rd quarter
Year-end
Total
(Yen)
(Yen)
(Yen)
(Yen)
(Yen)
Year ended March 31, 2025
-
115.00
-
75.00
190.00
Year ending March 31, 2026
-
Year ending March 31, 2026 (Forecast)
95.00
-
95.00
190.00
Note: Revisions to the forecast of cash dividends most recently announced: None
The dividends per share for the 2nd quarter of the year ended March 31, 2025 consist of an ordinary dividend of ¥75.00 and a bonus dividend of ¥40.00.
-
Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)
(Percentage indicates year-on-year change)
Net sales
Operating profit
Ordinary profit
Profit attributable to owners of the parent
Basic earnings per share
(Million yen)
(%)
(Million yen)
(%)
(Million yen)
(%)
(Million yen)
(%)
(Yen)
Year ending
March 31, 2026
88,000
(6.4)
5,200
(75.3)
6,000
(71.8)
3,400
(75.6)
89.79
Note: Revisions to the financial forecast most recently announced: None
- Notes
Significant changes in the scope of consolidation during the period: None
Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes
Changes in accounting policies, changes in accounting estimates, and restatement
Changes in accounting policies due to revisions to accounting standards and other regulations: None
Changes in accounting policies other than 1): None
Changes in accounting estimates: None
Restatement: None
Number of issued shares (common stock)
1) Number of issued shares at the end of the period (including treasury stock) | As of June 30, 2025 | 44,139,730 shares | As of March 31, 2025 | 45,939,730 shares |
2) Number of treasury shares at the end of the period | As of June 30, 2025 | 6,274,760 shares | As of March 31, 2025 | 7,535,854 shares |
3) Average number of shares during the period | Three-Month period of Fiscal 2025 | 38,042,686 shares | Three-Month period of Fiscal 2024 | 37,869,727 shares |
Note: The number of treasury shares at the end of the period includes the Company's shares held by the "Board Benefit Trust (BBT)" and the "Employee Stock Ownership Plan (J-ESOP)" (203,600 shares as of June 30, 2025 and 93,600 shares as of March 31, 2025). The Company's shares held by the BBT and J-ESOP are included in the number of treasury stock to be deducted in the calculation of the average number of shares during the period (109,314 shares as of June 30, 2025 and 28,200 shares as of June 30, 2024).
Review of the Japanese-language originals of the attached quarterly consolidated financial results by certified public accountants or an audit corporation: None
Explanation of proper use of earnings forecasts, and other special matters:
(Caution regarding forward-looking statements)
The performance forecasts and other descriptions on future events presented in this material are based on information currently available and certain assumptions considered to be reasonable. The actual performance may differ from these forecasts.
How to review the supplementary material to the financial results reports:
It has been posted on the Company's web site, along with the financial results reports.
2. Consolidated Financial Results for Three-Month Period of Fiscal 2025-
Consolidated balance sheets
Fiscal 2024
(As of March 31, 2025)
(Millions of yen) Three-Month period of
Fiscal 2025
(As of June 30, 2025)
Assets
43,411
54,093
Cash and deposits
Current assets
Notes and accounts receivable - trade, and contract assets
21,178 21,627
Marketable securities
15,992
11,992
Merchandise and finished goods
8,805
8,554
Work in process
2,311
2,108
Raw materials and supplies
7,904
7,845
Other
1,091
1,093
Allowance for doubtful accounts
(0)
-
Total current assets
111,377
96,634
Non-current assets
Property, plant and equipment
Buildings and structures, net
15,530
16,282
Other, net
12,098
12,172
Total property, plant and equipment
27,629
28,455
Intangible assets
In-process research and development
4,400
4,400
Goodwill
14,035
14,016
Other
854
892
Total intangible assets
19,289
19,308
Investments and other assets
Investment securities
18,875
18,578
Other
13,251
13,364
Total investments and other assets
32,126
31,942
Total non-current assets
79,045
79,707
Total assets
190,422
176,341
Fiscal 2024
(As of March 31, 2025)
(Millions of yen) Three-Month period of
Fiscal 2025
(As of June 30, 2025)
Liabilities
Current liabilities
6,234
8,186
Notes and accounts payable - trade
Electronically recorded obligations -
operating
136
111
Short-term bank loans
3,850
3,850
Income taxes payable
7,285
255
Provision for bonuses
1,154
443
Other
9,741
10,946
Total current liabilities
30,354
21,842
Non-current liabilities
Provision for share-based remuneration
163
141
Net defined benefit liability
4,954
4,968
Deferred tax liabilities
1,514
1,514
Other
800
426
Total non-current liabilities
7,433
7,051
Total liabilities
37,787
28,894
Net assets
Shareholders' equity
Common stock
23,853
23,853
Capital surplus
12,932
11,406
Retained earnings
135,242
127,368
Treasury stock
(28,233)
(23,791)
Total shareholders' equity
143,794
138,837
Accumulated other comprehensive income
Net unrealized holding gain on securities
6,257
6,061
Foreign currency translation adjustment
(57)
(57)
Remeasurements of defined benefit plans
2,640
2,606
Total accumulated other comprehensive income
8,840
8,609
Total net assets
152,634
147,447
Total liabilities and net assets
190,422
176,341
- Consolidated statements of income and comprehensive income (Consolidated statements of income)
Three-Month period of Fiscal 2024
(April 1, 2024 - June 30, 2024)
(Millions of yen) Three-Month period of
Fiscal 2025
(April 1, 2025 - June 30, 2025)
Net sales | 18,254 | 18,867 |
Cost of sales | 8,202 | 8,995 |
Gross profit | 10,052 | 9,872 |
Selling, general and administrative expenses | ||
Salaries | 1,411 | 1,418 |
Bonuses and provision for bonuses | 277 | 269 |
Retirement benefit expenses | 41 | 43 |
Research and development expenses | 2,998 | 5,382 |
Other | 2,573 | 2,744 |
Total selling, general and administrative expenses | 7,301 | 9,858 |
Operating profit | 2,750 | 14 |
Other income | ||
Interest income | 4 | 43 |
Dividends income | 284 | 316 |
Foreign exchange gains | - | 57 |
Other | 16 | 9 |
Total other income | 306 | 428 |
Other expenses | ||
Interest expenses | 5 | 10 |
Foreign exchange losses | 19 | - |
Loss on investments in investment partnership | 7 | 7 |
Other | 12 | 6 |
Total other expenses | 45 | 24 |
Ordinary profit | 3,011 | 417 |
Extraordinary income | ||
Other | - | 1 |
Total extraordinary income | - | 1 |
Extraordinary losses | ||
Loss on retirement of non-current assets | 33 | 4 |
Loss on valuation of investment securities | 605 | 2 |
Other | - | 2 |
Total extraordinary losses | 639 | 9 |
Profit before income taxes | 2,371 | 409 |
Income taxes | 617 | 137 |
Profit | 1,754 | 271 |
Profit attributable to owners of the parent | 1,754 | 271 |
Three-Month period of Fiscal 2024
(April 1, 2024 - June 30, 2024)
(Millions of yen) Three-Month period of
Fiscal 2025
(April 1, 2025 - June 30, 2025)
Profit 1,754 271
Other comprehensive income
Net unrealized holding gain on securities 94 (196)
Deferred gains or losses on hedges (221) -
Remeasurements of defined benefit plans | (20) (34) |
Total other comprehensive income | (146) (230) |
Comprehensive income | 1,607 40 |
Total comprehensive income attributable to | |
owners of the parent | 1,607 40 |